COLUMBUS, Ohio and PITTSBURGH, Nov. 1 /PRNewswire/ -- Two emerging
nanotechnology companies announced a broad cross-licensing agreement that will
extend the market reach and technical utility of their fluorescent
biomolecular assaying platforms.
BioCrystal Ltd., based in Columbus, Ohio, and Crystalplex Corp., based in
Pittsburgh, Pa., also said they agreed to collaborate on the development of
novel products using the proprietary technologies of each company. The
agreement also provides for possible joint product distribution.
The agreement combines highly complementary technologies for producing
fluorescent semiconducting nanocrystals and nanobeads, which are gaining
increasing use in the detection of low-abundance molecules in biological
research and clinical diagnosis.
In particular, BioCrystal provided Crystalplex with a non-exclusive
worldwide license to its intellectual property related to nanocrystal-encoded
beads and a nanocrystal-enhanced filter set for microscopy applications.
BioCrystal will also allow Crystalplex to use non-water-soluble nanocrystals
for encoding into Crystalplex's PlxBead products and its water-soluble
nanocrystals products for sale with Crystalplex PlxBeads.
Crystalplex provided BioCrystal with a nonexclusive worldwide sublicense
to its alloyed nanocrystal technology licensed from Indiana University.
"Crystalplex is delighted to forge a working relationship with such a
strong technology leader," said Alan R. Seadler, Ph.D., president and CEO of
Crystalplex. "This collaboration will have a major impact on the future of
fluorescent nanocrystals as platforms for highly multiplexed and ultra-
sensitive molecular detection."
"Crystalplex has a clear vision of what it expects to accomplish with its
bead-based technology," said Jeffrey R. Bergen, president and CEO of
BioCrystal. "We are pleased to have this opportunity to broaden biological and
clinical applications for fluorescent nanocrystal products."
About Crystalplex Corp. ( http://crystalplex.com )
Crystalplex is an early stage company providing cutting-edge, bead-based
nanotechnology "PlxBeads" to the biomedical research and medical diagnostic
markets. Plxbeads can be used as "molecular barcodes" to monitor complex
biological processes in pharmaceutical research or as nanosensors reporting
diagnostic results for complex diseases. Crystalplex products will provide
test results from smaller samples and with reduced time, lower labor costs,
and less expensive instrumentation than currently possible while also
providing better results for drug discovery or diagnostic decision making.
Crystalplex was founded by LaunchCyte LLC and has been funded by private
investors as well as Innovation Works, the Pittsburgh Life Sciences
Greenhouse, and the University of Pittsburgh Medical Center.
About BioCrystal, Ltd. (( http://www.biocrystal.com )
Formed in 1996, BioCrystal, Ltd., brought together an interdisciplinary
science group into a business structure committed to the development of novel
products and procedures for applications in the life sciences and clinical
medicine. Funded by private investment sources in Columbus, Ohio, BioCrystal
has created a vital, high technology business environment in which products
are being developed for commercialization in three areas: semiconductor-based,
nanocrystalline fluorescent markers (BioPixels(TM)) for cell and intracellular
detection and analysis; therapeutic compounds and procedures for the diagnosis
and treatment of cancer; and OptiCell (R), a versatile, disposable tool for
broad use in cell and tissue culture. BioCrystal has 36 patents and allowed
patent applications in the three technology areas.
SOURCE Crystalplex Corp.